Weekly Recap | JIANGXI BIO -9.23%, consensus target above spotWeekly Review·2 days ago, 07:22 AM06915-4.95%
The 2026 Survival Guide: Real Profits, Fake Pivots, and Executive Musical ChairsGlobal Report·Sep 8 at 11:32 AM01164-6.36%08471-5.56%
The Unbundling of Hong Kong Equities: A Value Chain PerspectiveGlobal Report·Sep 8 at 10:20 AM06915-4.95%06049+0.29%
Weekly Recap | JIANGXI BIO -10.63%, interim profit falls 60.99%Weekly Review·Sep 5 at 05:43 AM06915-4.95%
Jiangxi Institute of Biological Products FY26 H1 profit drops 60.99% to RMB 14.37 million; revenue falls 16.5% to RMB 83.29 millionPUBT·Aug 31 at 09:18 AM06915-4.95%
Weekly Recap | JIANGXI BIO +13.89%, consensus target above spotWeekly Review·Aug 29 at 04:55 AM06915-4.95%
Weekly Recap | JIANGXI BIO +10.57%, new coverage flags antiserum platform pivotWeekly Review·Aug 22 at 04:22 AM06915-4.95%
Jiangxi Institute of Biological Products schedules board meeting to release interim resultsPUBT·Aug 17 at 08:34 AM06915-4.95%
